Drug Profile
ATH 06
Alternative Names: AFFITOPE® AT06A+adjuvant; AT06A; ATH06Latest Information Update: 02 Jun 2021
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Antihyperlipidaemics; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 31 May 2021 AFFiRiS has patent protection for PCSK9 peptide vaccine in USA, Australia, and Europe
- 31 May 2021 AFFiRiS has patents pending for PCSK9 peptide vaccine in the Canada and Japan
- 27 May 2021 Immunogenecity and adverse events data from a phase I AFF012 trial in Atherosclerosis (In volunteers) released by AFFiRiS